A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
Condition(s):Lung CancerLast Updated:September 2, 2015Unknown status
Hide Studies Not Open or Pending
Condition(s):Lung CancerLast Updated:September 2, 2015Unknown status
Condition(s):Schizophrenia; Schizoaffective DisorderLast Updated:January 23, 2018Terminated
Condition(s):Irritable Bowel SyndromeLast Updated:February 21, 2021Completed
Condition(s):PeriodontitisLast Updated:December 13, 2019Unknown status
Condition(s):Lupus Nephritis; SLE NephritisLast Updated:January 25, 2024Recruiting
Condition(s):Non-Alcoholic Fatty Liver Disease; Insulin Resistance; Glucose Tolerance Impaired; Obesity, AbdominalLast Updated:February 3, 2021Completed
Condition(s):Oral Submucous FibrosisLast Updated:January 5, 2016Unknown status
Condition(s):Tinnitus, SubjectiveLast Updated:April 20, 2023Active, not recruiting
Condition(s):HalitosisLast Updated:August 9, 2023Completed
Condition(s):Exercise Induced Muscle DamageLast Updated:April 26, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.